NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

The tumor, which occurs when supportive cells in the brain grow and divide uncontrollably, is extremely aggressive and deadly. Most patients survive only 14 to 16 months after diagnosis.

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) ...

One woman received more than 100 cycles of 'unnecessary' chemotherapy treatment at University Hospital Coventry ...

Linda Scelza knew what would happen when she told her son, Ryder, it was “OK to go.” Ryder Scelza took two more breaths and then died in his her arms, she said. He was 21. Ryder Scelza, of Rocky Hill, ...

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA ...

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTO ...

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental ...

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical ...